Cosmos Health: A Company Transformed — 2026 Year-to-Date

A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026

CHICAGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ: COSM) today presents a comprehensive corporate update covering all significant operational, financial, and strategic milestones from January 1, 2026 through August 31, 2026.

The Company has executed across every dimension of its stated strategy in 2026: record revenue in every reporting period, a deleveraged and simplified balance sheet, a growing proprietary IP portfolio, meaningful U.S. brand launches, accelerating international expansion, AI-led operational upgrades, and active share repurchases. The update below is structured to give investors a complete view of that transformation.

I. Financial Performance: Three Consecutive Record Periods

Cosmos Health has delivered its highest revenue in Company history across every reporting period in 2026, building on a record FY2025:

FY2025: Revenue $65.27M (+20% YoY) — the strongest annual result in Company history. Gross profit surged 83% to $7.9M. Gross margin expanded 418 basis points. Adjusted EPS improved 82%. Cash rose more than tenfold to $3.5M. Every core segment contributed: CosmoFarm expanded its pharmacy network, Cana scaled contract manufacturing under long-term agreements, Decahedron grew UK distribution, and Sky Premium Life expanded globally.

Q1 2026: Revenue $17.93M (+30.7%) — record Q1. Total liabilities declined $4.5M (-9.6%). Stockholders’ equity +7.6%. Liabilities-to-assets ratio improved to 68.2% from 71.9% at year-end 2025. Adjusted EBITDA near breakeven. Broad-based commercial strength: 75+ pharmacies added at CosmoFarm, Sky Premium Life growth across multiple markets, expanded Cana orderbook.

Q2 2026: Revenue $18.99M (+28.8%) — record Q2. H1 2026 $36.91M (+29.7%). Adjusted gross profit +58% YoY. Total liabilities −$6.27M (−13.3%). Stockholders’ equity +12.2%. Liabilities-to-assets ratio improved 550 basis points. Annualized adjusted run-rate exceeded $75M. Every core division contributed: CosmoFarm 75+ pharmacies, Cana orderbook 25M+ units all-time high, Decahedron near-doubled UK revenue.

Operating Efficiency: operating cash requirements in H1 2026 ran more than 30% below the average of the prior two years, reflecting revenue growth, operating efficiencies and disciplined cost control — a meaningful step toward the Company’s 2027 profitability targets.

II. Strengthened Balance Sheet and Capital Structure

The most consequential financial development of 2026 is the transformation of Cosmos Health’s capital structure. The Company has methodically removed meaningful dilution overhang mechanisms and, as a result, expects its share count to remain broadly stable under its existing capital structure, before accounting for the reduction from ongoing share repurchases.

III. Diversified Asset Base and Digital Assets Strategy

The Company maintains a diversified asset base spanning liquid assets, digital holdings and real estate, alongside access to non-dilutive financing. Together these provide flexibility to fund the Company’s next phase of growth without recourse to equity issuance. As previously stated, the Company has identified approximately $20 million in non-core assets for potential monetization that can be converted to liquidity without impacting core operations. These primarily comprise digital assets, in which over $3 million has been invested to date, and a real estate portfolio with a fair market value of approximately $15 million.

Digital Assets

Cosmos Health has built a disciplined digital asset program as a component of its treasury strategy, with initial focus on Ethereum and strategic expansion into Bitcoin:

Real Estate

Beyond its liquid and digital assets, Cosmos Health owns a valuable real estate portfolio, with an independent fair market valuation placing it at approximately $15 million. The portfolio comprises the Cana Laboratories’ manufacturing facility in Athens, on a land plot of approximately 54,000 square feet, and the CosmoFarm logistics center in western Athens, of approximately 29,100 square feet. Both properties are wholly owned by the Company. Management regards this as a further resource available to the Company.

European Investment Bank financing

In May 2026, Cana Laboratories entered into an advisory agreement with the European Investment Bank (EIB) for the financing of a €50 million R&D program, under which EIB financing could represent up to 50%, or €25 million, under the EIB’s Venture Debt Program. This sits alongside available credit facilities and other non-dilutive financing sources that may be explored.

IV. Analyst Coverage and Valuation

On January 14, 2026, Zacks Small-Cap Research initiated analyst coverage of Cosmos Health with a $4.50 price target — representing a significant premium to where the stock has traded. The initiation cited the Company’s revenue trajectory, brand portfolio and proprietary pipeline as key drivers. Analyst estimates and price targets represent the views of the issuing firm and not those of the Company.

V. Divisional Performance Snapshot

VI. UK Retail Breakthrough, New Channels and Growth Initiatives

In February 2026, Cosmos Health achieved a landmark dual placement for C-Scrub in the United Kingdom — securing listings with two of the largest retailers in the country:

The listing in both retailers represents a step-change in C-Scrub’s UK visibility and credibility, and establishes a platform for potential rollout of additional Cosmos Health products. The Company has since extended the franchise into two additional channels:

Acquisitions

The Company is actively exploring acquisitions that could be immediately accretive and accelerate progress toward its stated guidance targets. Two letters of intent (LOI) have been signed to date:

VII. International Expansion: Saudi Arabia, Dubai, and Global Markets

Cosmos Health accelerated the international rollout of its proprietary brands during 2026, adding exclusive and long-term distribution partnerships across the Gulf while achieving full European coverage for Sky Premium Life. Each agreement is with an established distributor holding significant retail reach in its market.

Saudi Arabia (August 2026): Cosmos Health entered the Kingdom of Saudi Arabia through an exclusive five-year distribution agreement with Innova Healthcare, one of the Kingdom’s largest retail pharmacy networks, operating more than 250 pharmacies with a stated plan to exceed 500. The agreement covers the full Sky Premium Life range. An initial purchase order of 126,000 units was secured on execution, with total expected volume exceeding 5 million units over the initial five-year term. Innova holds a first right of refusal on new Cosmos Health products developed or acquired during the term.

Qatar (June 2026): The Company signed a distribution agreement with International Medical Company, whose Kulud Pharmacies retail arm is the country’s largest chain with more than 130 branches, securing an initial order of 31,000 Sky Premium Life units.

United Arab Emirates (April 2026): A third consecutive purchase order was received from Pharmalink for 60,000 Sky Premium Life units, taking cumulative orders to 270,000 units against a five-year goal of over 3 million units.

European Union (June 2026): Pan-European distribution was achieved for Sky Premium Life through the e-commerce platform Skroutz, making 96 products available for shipment across all 27 EU Member States.

Albania (July 2026): Pharma Cell partnership scaled to 4,500+ monthly units, with annualized orders projected to exceed 54,000 units. Products are distributed across Albania and recommended by healthcare professionals.

Dubai (February 2026): Cosmos Health showcased its expanding brand portfolio at the World Health Expo Dubai 2026, reinforcing the Company’s presence in the Middle East and MENA region.

VIII. CCX0722 Hydrogel: International Patent in Four Markets

On June 25, 2026, Cana Laboratories advanced international patent application WO2025108566A1, “Hydrogel for Body Weight Management,” into the European regional phase and national phases in the United States, Australia and Canada. The IP was acquired outright from Cloudpharm on June 8, 2026 — no licensing fees, no royalty-sharing, no third-party dependency.

CCX0722 works through a simple, mechanical mechanism with no systemic absorption. Taken as a capsule before meals, the dried hydrogel absorbs water in the stomach and swells more than 100-fold into soft gel pieces that occupy stomach volume to support satiety, before naturally passing through the GI tract. The global weight management market was $190.6B in 2025 and is projected to reach $562.2B by 2033 at a 14.2% CAGR.

IX. U.S. Proprietary Brand Buildout: The 18 Series Platform

The 18 Series is Cosmos Health’s portfolio of science-validated nutraceutical products, manufactured in the United States at facilities holding GMP certification and FDA registration. The following products are now in active U.S. commercial launch or production:

Combined, the 18 Series / NOOR U.S. portfolio projects over $22.7M in annualized revenue at approximately $17.0M in gross profit — structurally high-margin, DTC-led, and subscription-capable.

X. AI Strategy and Operational Infrastructure

AI has moved from strategy to execution at Cosmos Health in 2026, with deployments across commercial, logistics and research functions:

These investments underpin the operating leverage the Company expects to demonstrate as revenue scales toward $90M and beyond.

XI. 2026–2029 Financial Guidance Reaffirmed

The Company reaffirms its guidance issued May 26, 2026. H1 2026 performance is consistent with the trajectory required to achieve these targets:

The 32% CAGR is expected to be driven by a structural margin shift toward proprietary segments: the 18 Series (72–75% gross margins), CCX0722 licensing/co-development, and Cana contract manufacturing — alongside continued organic growth in distribution.

Management believes that achieving these targets would create significant value for shareholders, as the Company transitions to a self-funded model driven by strong cash flows.

XII. Complete 2026 Milestone Timeline

Management Commentary

Greg Siokas, CEO of Cosmos Health, stated: “This is a different company than it was twelve months ago. We have retired $8 million of debt a full year early. We repurchased more than five million shares. We delivered record revenue in every reporting period. We placed C-Scrub in Tesco and Superdrug. We entered Saudi Arabia with a five-year exclusive distribution agreement. We filed our hydrogel patent across four global markets. We launched proprietary U.S. brands. And we did all of this while cutting our cash burn by more than 30%.

“Every pillar of our strategy is delivering. CosmoFarm is growing its pharmacy network and deploying AI. Cana has its biggest contract manufacturing orderbook in history. Decahedron nearly doubled its UK revenue. Our proprietary brands are gaining real commercial traction.

“We enter the second half of 2026 with a solid balance sheet and a streamlined capital structure, growing revenue across every division, and a clear path to $200 million in revenue and significant profitability by 2029. Cosmos is not a promise. It is performance.”

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website ( www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.

Investor Relations Contact:

BDG Communications

cosm@bdgcommunications.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b3c3061f-2b75-4eaf-9ca4-2e98bdd664b2